Onego Bio has secured $40 million in Series A funding to advance the commercialization and production of sustainable bioidentical egg protein, positioning it as a leader in the alternative protein market.

Target Information

Onego Bio is an innovative company specializing in the development of animal-free bioidentical egg protein through precision fermentation—a contemporary food technology aimed at producing a range of products that require egg functionalities, such as baked goods, mayonnaise, omelettes, and nougat fillings.

The company's product, Bioalbumen®, serves as a suitable and nutritious substitute for traditional egg proteins, boasting a complete amino acid profile and exceptional functional characteristics, making it an attractive option for food manufacturers seeking reliable and sustainable sources of egg protein.

Industry Overview

The global egg market is currently facing significant fluctuations, largely driven by challenges such as avian flu outbreaks and the growing demand for cage-free eggs